Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial.
Thiago Ramos GrigioAngela Maria SousaGabriel Guimarães Nunes MagalhãesHazem Adel AshmawiJoaquim Edson VieiraPublished in: Clinics (Sao Paulo, Brazil) (2020)
The addition of aprepitant as a third antiemetic resulted in no significant reduction in the incidence of PONV in this population. However, the incidence of PONV was reduced in relation to the general population.